Lawrence B. Cohen’s RenovoRx RNXT Stock Holding History

Lawrence B. Cohen’s Portfolio RNXT Stock Details RNXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-97,165	Closed	-$129K	–	47
2023 Q3	$129K	Hold	97,165	–	–	0.09%	58
2023 Q2	$220K	Hold	97,165	–	–	0.14%	61
2023 Q1	$339K	Hold	97,165	–	–	0.23%	53
2022 Q4	$228K	Hold	97,165	–	–	0.12%	86
2022 Q3	$196K	Hold	97,165	–	–	0.15%	61
2022 Q2	$192K	Buy	97,165 +43,044	+80%	+$88K	0.14%	60
2022 Q1	$159K	Buy	+54,121	New	+$190K	0.09%	61

Other funds holding RNXT

NPT

Nixon Peabody Trust Boston, Massachusetts $1.41B AUM 27.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

ACA

Affinity Capital Advisors Berkeley, California $810M AUM 24.85% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Lawrence B. Cohen's RNXT Position: Q4 2023 in Review

Lawrence B. Cohen sold out of RenovoRx (RNXT) in Q4 2023, closing a stake of 97,165 shares — an estimated $129K sold.

Lawrence B. Cohen first reported a position in RNXT in Q1 2022 and held it in 7 quarters. The position peaked at $339K in Q1 2023. 12 funds tracked by Wall St. Rank hold RNXT as of Q4 2023.

Lawrence B. Cohen reported no remaining RenovoRx position as of Q4 2023 after selling out during the quarter.
Lawrence B. Cohen sold 97,165 RenovoRx shares in Q4 2023, an estimated $129K.
Lawrence B. Cohen first reported a position in RenovoRx in Q1 2022 and held it in 7 quarters.
Lawrence B. Cohen's RenovoRx position peaked at $339K in Q1 2023.
12 funds tracked by Wall St. Rank held RenovoRx as of Q4 2023.

Based on Lawrence B. Cohen's 13F filing for Q4 2023, filed 9 Feb 2024.